132 related articles for article (PubMed ID: 37987186)
21. Atherogenic dyslipidemia, but not hyperglycemia, is an independent factor associated with liver fibrosis in subjects with type 2 diabetes and NAFLD: a population-based study.
Julián MT; Pera G; Soldevila B; Caballería L; Julve J; Puig-Jové C; Morillas R; Torán P; Expósito C; Puig-Domingo M; Castelblanco E; Franch-Nadal J; Cusi K; Mauricio D; Alonso N
Eur J Endocrinol; 2021 Apr; 184(4):587-596. PubMed ID: 33606661
[TBL] [Abstract][Full Text] [Related]
22. A population-based study on the prevalence of NASH using scores validated against liver histology.
Hyysalo J; Männistö VT; Zhou Y; Arola J; Kärjä V; Leivonen M; Juuti A; Jaser N; Lallukka S; Käkelä P; Venesmaa S; Simonen M; Saltevo J; Moilanen L; Korpi-Hyövalti E; Keinänen-Kiukaanniemi S; Oksa H; Orho-Melander M; Valenti L; Fargion S; Pihlajamäki J; Peltonen M; Yki-Järvinen H
J Hepatol; 2014 Apr; 60(4):839-46. PubMed ID: 24333862
[TBL] [Abstract][Full Text] [Related]
23. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD.
Kalavalapalli S; Leiva EG; Lomonaco R; Chi X; Shrestha S; Dillard R; Budd J; Romero JP; Li C; Bril F; Samraj G; Pennington J; Townsend P; Orlando F; Shetty S; Mansour L; Silva-Sombra LR; Bedossa P; Malaty J; Barb D; Gurka MJ; Cusi K
J Clin Endocrinol Metab; 2023 Apr; 108(5):1192-1201. PubMed ID: 36378995
[TBL] [Abstract][Full Text] [Related]
24. Impact of steatotic liver disease and non-alcoholic steatohepatitis on cognitive impairment in people living with HIV: A cross-sectional study.
Han WM; Hiransuthikul A; Holroyd KB; Apornpong T; Lwin HM; Gatechompol S; Ubolyam S; Kerr S; Avihingsanon A;
HIV Med; 2023 Dec; 24(12):1233-1243. PubMed ID: 37975283
[TBL] [Abstract][Full Text] [Related]
25. Advanced liver fibrosis predicts heart failure and hospitalizations in people with type 2 diabetes: A prospective cohort study from Hong Kong Diabetes Register.
Kong AP; Lau ES; O CK; Luk AO; Yip TC; Chow EY; Kwok R; Lee HW; Wong GL; Ma RC; Chan HL; Wong VW; Chan JC
Diabetes Res Clin Pract; 2023 Aug; 202():110825. PubMed ID: 37442241
[TBL] [Abstract][Full Text] [Related]
26. Not only type 2 diabetes but also prediabetes is associated with portal inflammation and fibrosis in patients with non-alcoholic fatty liver disease.
Yilmaz Y; Senates E; Yesil A; Ergelen R; Colak Y
J Diabetes Complications; 2014; 28(3):328-31. PubMed ID: 24602757
[TBL] [Abstract][Full Text] [Related]
27. Prevalence and Predictors of Non-Alcoholic Fatty Liver Disease in Morbidly Obese South Indian Patients Undergoing Bariatric Surgery.
Praveenraj P; Gomes RM; Kumar S; Karthikeyan P; Shankar A; Parthasarathi R; Senthilnathan P; Rajapandian S; Palanivelu C
Obes Surg; 2015 Nov; 25(11):2078-87. PubMed ID: 25835982
[TBL] [Abstract][Full Text] [Related]
28. Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
Li G; Rios RS; Wang XX; Yu Y; Zheng KI; Huang OY; Tang LJ; Ma HL; Jin Y; Targher G; Byrne CD; Pan XY; Zheng MH
Br J Nutr; 2022 Jun; 127(11):1613-1620. PubMed ID: 34176541
[TBL] [Abstract][Full Text] [Related]
29. Approach to the Patient With Nonalcoholic Fatty Liver Disease.
Belfort-DeAguiar R; Lomonaco R; Cusi K
J Clin Endocrinol Metab; 2023 Jan; 108(2):483-495. PubMed ID: 36305273
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
[TBL] [Abstract][Full Text] [Related]
31. Increased prevalence and risk of non-alcoholic fatty liver disease in overweight and obese patients with Type 2 diabetes in South China.
Yi M; Chen RP; Yang R; Chen H
Diabet Med; 2017 Apr; 34(4):505-513. PubMed ID: 27334577
[TBL] [Abstract][Full Text] [Related]
32. Women Have a Lower Risk of Nonalcoholic Fatty Liver Disease but a Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis.
Balakrishnan M; Patel P; Dunn-Valadez S; Dao C; Khan V; Ali H; El-Serag L; Hernaez R; Sisson A; Thrift AP; Liu Y; El-Serag HB; Kanwal F
Clin Gastroenterol Hepatol; 2021 Jan; 19(1):61-71.e15. PubMed ID: 32360810
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes.
Kuchay MS; Choudhary NS; Mishra SK; Misra A
Diabetes Metab Syndr; 2020; 14(6):2233-2239. PubMed ID: 33336648
[TBL] [Abstract][Full Text] [Related]
34. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease.
Nascimbeni F; Bedossa P; Fedchuk L; Pais R; Charlotte F; Lebray P; Poynard T; Ratziu V;
J Hepatol; 2020 May; 72(5):828-838. PubMed ID: 31862486
[TBL] [Abstract][Full Text] [Related]
35. Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.
Walle P; Takkunen M; Männistö V; Vaittinen M; Lankinen M; Kärjä V; Käkelä P; Ågren J; Tiainen M; Schwab U; Kuusisto J; Laakso M; Pihlajamäki J
Metabolism; 2016 May; 65(5):655-666. PubMed ID: 27085774
[TBL] [Abstract][Full Text] [Related]
36. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
[TBL] [Abstract][Full Text] [Related]
37. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study.
Nah EH; Cho S; Park H; Noh D; Kwon E; Cho HI
PLoS One; 2021; 16(11):e0260477. PubMed ID: 34818372
[TBL] [Abstract][Full Text] [Related]
38. The epidemiology of non-alcoholic steatohepatitis (NASH) in the United States between 2010-2020: a population-based study.
Hamid O; Eltelbany A; Mohammed A; Alsabbagh Alchirazi K; Trakroo S; Asaad I
Ann Hepatol; 2022; 27(5):100727. PubMed ID: 35700934
[TBL] [Abstract][Full Text] [Related]
39. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of non-alcoholic fatty liver disease (NAFLD) in a cohort of patients with type 2 diabetes: the PHIGNA-DM2 study.
Martínez-Ortega AJ; Piñar Gutiérrez A; Lara-Romero C; Remón Ruiz PJ; Ampuero-Herrojo J; de Lara-Rodríguez I; Romero-Gómez M; García Luna PP; Soto-Moreno A
Nutr Hosp; 2022 Oct; 39(5):1012-1018. PubMed ID: 36134588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
